Nextech Invest, Ltd.

Fundamental concentrated ★Highest signal healthcare specialist (100%) CIK 1595430
League rank
#24
in Fundamental concentrated · #26 overall
Long book
$1.42B
Q1 2026
Positions
17
Top-10 weight
96%
concentration
Last quarter
+54.7%
SPY +14.8%
Turnover
17%
of book per quarter

Strategy in plain words

auto-generated from filings

Nextech Invest, Ltd. is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $1.42B US long book across 17 positions.

The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is modest: positions are typically held for years. Current anchor positions: REVOLUTION MEDICINES INC, TYRA BIOSCIENCES INC, TANGO THERAPEUTICS INC, ORIC PHARMACEUTICALS INC, ALUMIS INC.

Over the last 5 quarters its long book ran on average 30.2pp per quarter ahead of the S&P 500, beating the index in 5 of 5 quarters. We rate its filings highest-signal: new buys here are worth attention.

Implied long-book return vs S&P 500

methodology: positions priced quarterly, no shorts/options
Fund long book S&P 500
Q1 2025
+15.3%
Q2 2025
+27.3%
Q3 2025
+51.7%
Q4 2025
+34.3%
Q1 2026
+54.7%

Sector allocation

Healthcare
100%

Long book by quarter

$430.3M
Q1 2025
$528.4M
Q2 2025
$657.0M
Q3 2025
$1.03B
Q4 2025
$1.42B
Q1 2026

What does Nextech Invest, own?

Q1 2026 13F
CompanySectorSharesValue% of bookChange
RVMD REVOLUTION MEDICINES INCHealthcare7.6M$739.2M52.0%Held
TYRA TYRA BIOSCIENCES INCHealthcare4.1M$155.3M10.9%Held
TNGX TANGO THERAPEUTICS INCHealthcare7.3M$152.0M10.7%Held
ORIC ORIC PHARMACEUTICALS INCHealthcare7.2M$90.8M6.4%Held
ALMS ALUMIS INCHealthcare3.5M$78.0M5.5%+21.4%
RLAY RELAY THERAPEUTICS INCHealthcare5.5M$55.0M3.9%+17.5%
ZYME ZYMEWORKS INCHealthcare1.1M$27.9M2.0%Held
KYMR KYMERA THERAPEUTICS INCHealthcare278.9K$23.2M1.6%Held
CTMX CYTOMX THERAPEUTICS INCHealthcare4.4M$20.9M1.5%New
CNTX CONTEXT THERAPEUTICS INCHealthcare7.4M$19.4M1.4%Held
CGEM CULLINAN THERAPEUTICS INCHealthcare1.1M$16.2M1.1%Held
ENGN enGene Therapeutics IncHealthcare2.3M$15.8M1.1%+9.4%
CRVS CORVUS PHARMACEUTICALS INCHealthcare450.0K$6.6M0.5%New
ARVN ARVINAS INCHealthcare539.4K$5.7M0.4%Held
GLUE MONTE ROSA THERAPEUTICS INCHealthcare304.2K$5.0M0.4%+9.0%
SPRY ARS PHARMACEUTICALS INCHealthcare610.7K$4.9M0.3%-7.6%

13F filing history

PeriodFormFiledEntriesReported valueFlagsSource
Q1 202613F-HRMay 15, 202617$1.42B canonicalSEC ↗
Q4 202513F-HRFeb 17, 202616$1.03B canonicalSEC ↗
Q3 202513F-HRNov 14, 202515$657.0M canonicalSEC ↗
Q2 202513F-HRAug 14, 202516$528.4M canonicalSEC ↗
Q1 202513F-HRMay 15, 202515$430.3M canonicalSEC ↗